Chelation therapy of manganese intoxication with para-aminosalicylic acid (PAS) in Sprague-Dawley rats.

Chelation therapy of manganese intoxication with para-aminosalicylic acid (PAS) in Sprague-Dawley rats.
复制标题

DOI:
10.1016/j.neuro.2008.12.007
复制
发表时间:
2009-03
期刊:
影响因子:
3.4
通讯作者:
Cowan DM
Cowan DM
中科院分区:
医学3区
文献类型:
--
作者:
Zheng W;Jiang YM;Zhang Y;Jiang W;Wang X;Cowan DM

文献摘要

参考文献

被引文献

相似文献

对氨基水杨酸 (PAS) 是 FDA 批准的抗结核药物,已成功用于治疗人类严重的锰 (Mn) 诱发的帕金森病。本研究旨在探讨 PAS 降低锰暴露动物体液和组织中锰浓度的能力。 Sprague-Dawley 大鼠每天腹膜内 (i.p.) 注射 6 mg Mn/kg,每周 5 天,持续 4 周,然后每日皮下 (sc.) 剂量的 PAS(PAS-L 和 PAS-H 组分别为 100 和 200 mg/kg),持续另外 2、3 或 6 周。锰暴露显着增加了血浆、红细胞(RBC)、脑脊液(CSF)、脑和软组织中锰的浓度。 PAS-H 治疗 3 周后,肝脏、心脏、脾脏和胰腺中的 Mn 水平显着降低 25% 至 33%,而 PAS-L 治疗 3 周没有显示任何效果。进一步使用 PAS-H 治疗 6 周,纹状体、丘脑、脉络丛、海马和额叶皮层的 Mn 水平降低了 16% 至 29%(p<0.05)。锰暴露大大增加了脑脊液、大脑和肝脏中铁 (Fe) 和铜 (Cu) 的浓度。 PAS-H 处理恢复了与对照相当的 Fe 和 Cu 水平。这些数据表明,PAS 可能充当螯合剂来动员和去除组织中的锰。高剂量和长期的 PAS 治疗对于其治疗效果似乎是必要的。
Para-aminosalicylic acid (PAS), an FDA-approved anti-tuberculosis drug, has been used successfully in the treatment of severe manganese (Mn)-induced Parkinsonism in humans. This study was conducted to explore the capability of PAS in reducing Mn concentrations in body fluids and tissues of Mn-exposed animals. Sprague-Dawley rats received daily intraperitoneally (i.p.) injections of 6 mg Mn/kg, 5 d/wk for 4 wks, followed by a daily subcutaneously (sc.) dose of PAS (100 and 200 mg/kg as the PAS-L and PAS-H group, respectively) for another 2, 3 or 6 wks. Mn exposure significantly increased the concentrations of Mn in plasma, red blood cells (RBC), cerebrospinal fluid (CSF), brain and soft tissues. Following PAS-H treatment for 3 wks, Mn levels in liver, heart, spleen and pancreas were significantly reduced by 25 to 33%, while 3 wks of PAS-L treatment did not show any effect. Further therapy with PAS-H for 6 wk reduced Mn levels in striatum, thalamus, choroid plexus, hippocampus and frontal cortex by 16 to 29% (p<0.05). Mn exposure greatly increased iron (Fe) and copper (Cu) concentrations in CSF, brain and liver. Treatment with PAS-H restored Fe and Cu levels comparable with control. These data suggest that PAS likely acts as a chelating agent to mobilize and remove tissue Mn. A high-dose and prolonged PAS treatment appears necessary for its therapeutic effectiveness.
DOI: 10.1097/01.jom.0000116900.49159.03
发表时间: 2004-03-01
影响因子: 3.2
作者:
Li, GJJ;Zhang, LL;Zheng, W
通讯作者: Zheng, W
DOI: 10.1111/j.1749-6632.1988.tb51416.x
发表时间: 1988-06-01
影响因子: 5.2
作者:
FENSTERMACHER, J;KAYE, T
通讯作者: KAYE, T
DOI: 10.1016/j.neuro.2006.02.003
发表时间: 2006-09-01
期刊: NEUROTOXICOLOGY
影响因子: 3.4
作者:
Li, G. Jane;Choi, Lyung-Sun;Zheng, Wei
通讯作者: Zheng, Wei
DOI: 10.1016/j.expneurol.2006.06.015
发表时间: 2006-12-01
影响因子: 5.3
作者:
Guilarte, Tomas R.;Chen, Ming-Kai;Schneider, Jay S.
通讯作者: Schneider, Jay S.
DOI: 10.1001/archneur.1989.00520460090018
发表时间: 1989-10-01
影响因子: --
作者:
HUANG, CC;CHU, NS;CALNE, DB
通讯作者: CALNE, DB